<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE301nnn/GSE301479/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301479</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>RNA-seq analysis of pulmonary arterial smooth muscle cells (PASMCs) and bronchial smooth muscle cells (BSMCs) after pulmonary arterial hypertension (PAH) treatment</name><description>Previous studies to determine transcriptional changes in PASMCs during PAH were affected by the inevitable contamination with BSMCs and venous SMCs. To specific target ASMCs, we generated an ASMC-effector mouse line by combining Cspg4/Acta2 intersectional genetics, enabling specific targeting of vascular SMCs, including PASMCs. To target non-vascular SMCs, including BSMCs, we generated the NVSMC-effector mouse line using Chrm2/Acta2 intersectional genetics. The development of ASMC-effector mice, excluding venous and BSMCs, enabled us to avoid such problems and determine PASMC-specific reactions after induction of PAH.</description><dates><publication>2026/04/11</publication></dates><accession>GSE301479</accession><cross_references><GSM>GSM9083862</GSM><GSM>GSM9083861</GSM><GSM>GSM9083864</GSM><GSM>GSM9083863</GSM><GSM>GSM9083866</GSM><GSM>GSM9083865</GSM><GSM>GSM9083868</GSM><GSM>GSM9083867</GSM><GSM>GSM9083869</GSM><GSM>GSM9083871</GSM><GSM>GSM9083860</GSM><GSM>GSM9083870</GSM><GPL>30172</GPL><GSE>301479</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>